Updates on histiocytic disorders. Issue 7 (9th March 2014)

• Record Type: Journal Article
• Authors: Vaiselbuh, Sarah R.; Bryceson, Yenan T.; Allen, Carl E.; Whitlock, James A.; Abla, Oussama
• Is Part Of: Pediatric blood & cancer. Volume 61:Issue 7(2014:Jul.)
• Page Start: 1329
• Page End: 1335
• Publication Date: 2014-03-09
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25017
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25017-sec-0001" sec-type="section"> <p>Histiocytic disorders are rare entities that are becoming more recognized as our understanding of the molecular pathogenesis lead to novel diagnostic tests and targeted drug development. A symposium held at the American Society of Pediatric Hematology/Oncology (ASPHO) 2013 Annual Meeting discussed new insights into histiocytic disorders. This review highlights the symposium presentations, divided into three sections encompassing Langerhans cell histiocytosis (LCH), hemophagocytic lymphohistiocytosis (HLH) and Rosai Dorfman disease (RDD) including subsections on pathogenesis, clinical diagnostic criteria and novel insights into treatment. Details of other histiocytic disorders as well as the standard treatment guidelines have been published elsewhere and are beyond the scope of this discussion [Haupt et al. (2013). Pediatr Blood Cancer 60:175–184; Henter et al. (2007). Pediatr Blood Cancer 48:124–131]. Pediatr Blood Cancer 2014;61:1329–1335. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>